CytoReason Ltd. announced that it will raise $20 million in a round of funding on September 20, 2022. The transaction will include participation from new investor, Pfizer Inc. The company will issue equity in the transaction.
Market Closed -
Other stock markets
|
After market 07:42:22 pm | |||
29.6 USD | +3.64% | 29.75 | +0.51% |
09:58am | Asymchem Laboratories Buys Pfizer's Former UK Site; Hong Kong Shares Slide 3% | MT |
09:15am | News Highlights : Top Company News of the Day - Thursday at 3 AM ET | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.81% | 168B | |
+37.74% | 723B | |
+34.95% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+16.49% | 244B | |
+9.72% | 208B | |
-4.54% | 205B | |
+7.43% | 166B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- CytoReason Ltd. announced that it expects to receive $20 million in funding from Pfizer Inc.